About us

HCD was created out of an alliance with University of Chester, charities and health service sectors in reponse to the ever-growing demand for economic analysis within healthcare and specifically the need for health economics and business intelligence within the public and third sectors.

Through these partnerships, HCD provides a unique insight and perspective, focusing our analyses on what matters to patients as well as decision-makers, all undertaken with academic rigour, independence and credibility.

Continue Reading
Scroll for more

Our Process

We have created core partnerships with University of Chester and leading patient charities that underpin our approach.

Higher education

Academia has a leading role to play in providing an independent, credible evidence-base as well as evaluating current and new ways of delivering healthcare.


Our partnerships with patient charities ensure that any analyses we undertake reflect the day-to-day realities of living with a particular condition.


We apply primary or secondary real world data sources depending on research needs and questions. From ethically reviewed burden of illness studies and bespoke service primary data, to secondary sourced disease registries and episode statistics.

Scroll for more

Current Vacancies

Scroll for more

Latest News

Check out what is happening at HCD Economics

Scroll for more

Get in touch

...and one of our experts will get back to you ASAP.

Please be advised that we will not use your details for marketing purposes
Scroll for more


Here are a few of the comments made by partners and clients about our collaborations

"The team at HCD Economics are ‘creative, responsive, knowledgeable, expert, agile, conscientious and reliable!’"

Burden of illness pharmaceutical industry partner


"I’ve worked with HCD Economics on a range of projects with excellent results including literature reviews, real world evidence generation and analyses, validation of outcomes measures, and designing outcomes studies. The team are very knowledgeable, very responsive to communications and always engaged in understanding the project requirements and the wider strategic requirements. I would not hesitate in recommending HCD Economics."

Shire plc


"At the British Liver Trust, we have been alarmed at the sharp increase in the number of people being diagnosed with NASH (non-alcoholic steatohepatitis) in the UK. They are often relatively young people in the prime of their lives and the diagnosis often comes as a complete shock. There has been scant research into the impact of NASH on patients’ quality of life, and on the direct and indirect costs of NASH to individuals and society. That is why the British Liver Trust welcomes the GAIN (Global Assessment of the Impact of NASH) study and is pleased to be involved in the research with HCD Economics."

Judi Rhys, CEO at BLT (British Liver Trust)

Scroll for more